The use of allogeneic NK cells has shown substantial clinical benefit against acute myeloid leukemia (AML) after haploidentical, partially mismatched, hematopoietic cell transplantation, when HLA-C incompatibility existed in the graft-versus-host (GVH) direction [20]. Here, HLA-C is linked to acute myeloid leukemia.